The pharmaceutical industry’s largest lobbying organization released guidelines on Tuesday to enhance racial and ethnic diversity among participants in clinical trials run by its member drug makers. The principles address a problem that has long hampered the development of new medicines and vaccines, including the studies of potential Covid-19 shots.
The group, PhRMA, noted that the guidelines are voluntary; they do not take effect until April 2021.
About the Author Reprints
